Edwards Lifesciences Corp insider trading
EWfinancial statementsForm 4 filings on EDGAR282 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at Edwards Lifesciences Corp bought $0 of stock in the open market, and 5 sold $3M. Officers and directors accounted for $0 of purchases and $3M of sales. The last reported transaction was an option exercise by Lippis Daniel J. on October 8, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 8, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $3MAug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
282 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | Lippis Daniel J. | CVP, TAVR | option exercise | 619 | $72.68 | $45K | 40,653 | Oct 8, 2026 |
| Oct 8, 2026 | Lippis Daniel J. | CVP, TAVR | open-market sale10b5-1 | 619 | $85.65 | $53K | 40,034 | Oct 8, 2026 |
| Sep 14, 2026 | Markowitz Wayne | CVP, JAPAC | tax withholding | 568 | $84.37 | $48K | 19,371 | Sep 14, 2026 |
| Sep 13, 2026 | Dahl Andrew M. | SVP, Corporate Controller | tax withholding | 253 | $84.37 | $21K | 14,615 | Sep 14, 2026 |
| Sep 11, 2026 | Markowitz Wayne | CVP, JAPAC | tax withholding | 355 | $86.77 | $31K | 19,939 | Sep 14, 2026 |
| Sep 11, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | tax withholding | 398 | $86.77 | $35K | 43,926 | Sep 11, 2026 |
| Sep 11, 2026 | Lippis Daniel J. | CVP, TAVR | option exercise | 619 | $72.68 | $45K | 40,653 | Sep 11, 2026 |
| Sep 11, 2026 | Lippis Daniel J. | CVP, TAVR | open-market sale10b5-1 | 619 | $87.51 | $54K | 40,034 | Sep 11, 2026 |
| Aug 31, 2026 | Dahl Andrew M. | SVP, Corporate Controller | open-market sale | 544 | $91.06 | $50K | 14,868 | Aug 31, 2026 |
| Aug 28, 2026 | Bruls Annette | CVP, EMEACLA | open-market sale | 2,644 | $89.98 | $238K | 17,984 | Aug 28, 2026 |
| Aug 26, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | option exercise | 31,800 | $72.68 | $2M | 76,124 | Aug 26, 2026 |
| Aug 26, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | open-market sale | 1,154 | $91.76 | $106K | 74,970 | Aug 26, 2026 |
| Aug 26, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | open-market sale | 30,646 | $90.99 | $3M | 44,324 | Aug 26, 2026 |
| Aug 26, 2026 | Markowitz Wayne | CVP, JAPAC | open-market sale | 1,240 | $91.47 | $113K | 20,294 | Aug 26, 2026 |
| Aug 11, 2026 | Lippis Daniel J. | CVP, TAVR | option exercise | 619 | $72.68 | $45K | 40,653 | Aug 11, 2026 |
| Aug 11, 2026 | Lippis Daniel J. | CVP, TAVR | open-market sale10b5-1 | 619 | $92.03 | $57K | 40,034 | Aug 11, 2026 |
| Jul 30, 2026 | Markowitz Wayne | CVP, JAPAC | open-market sale | 146 | $86.03 | $13K | 21,534 | Jul 30, 2026 |
| Jul 28, 2026 | Markowitz Wayne | CVP, JAPAC | option exercise | 9,628 | $74.02 | $713K | 31,308 | Jul 28, 2026 |
| Jul 28, 2026 | Markowitz Wayne | CVP, JAPAC | open-market sale | 9,628 | $85.06 | $819K | 21,680 | Jul 28, 2026 |
| Jul 27, 2026 | Zovighian Bernard J | CEO, Director | gift | 320 | $0.00 | — | 98,845 | Jul 27, 2026 |
| Jul 27, 2026 | Zovighian Bernard J | CEO, Director | giftindirect | 320 | $0.00 | — | 11,836 | Jul 27, 2026 |
| Jul 27, 2026 | Zovighian Bernard J | CEO, Director | open-market saleindirect | 2,921 | $83.93 | $245K | 8,916 | Jul 27, 2026 |
| Jul 11, 2026 | Bruls Annette | CVP, EMEACLA | tax withholding | 109 | $92.21 | $10K | 20,628 | Jul 13, 2026 |
| Jul 10, 2026 | Lippis Daniel J. | CVP, TAVR | option exercise | 619 | $72.68 | $45K | 40,653 | Jul 10, 2026 |
| Jul 10, 2026 | Lippis Daniel J. | CVP, TAVR | open-market sale10b5-1 | 619 | $91.70 | $57K | 40,034 | Jul 10, 2026 |
| Jul 9, 2026 | Mistras Theodora | CVP, Chief Financial Officer | award | 87,595 | $0.00 | — | 87,595 | Jul 10, 2026 |
| Jul 9, 2026 | Mistras Theodora | CVP, Chief Financial Officer | award | 12,325 | $0.00 | — | 99,920 | Jul 10, 2026 |
| Jul 7, 2026 | Lippis Daniel J. | CVP, TAVR | tax withholding | 377 | $95.18 | $36K | 40,034 | Jul 7, 2026 |
| Jun 30, 2026 | Lippis Daniel J. | CVP, TAVR | option exercise | 619 | $72.68 | $45K | 41,030 | Jun 30, 2026 |
| Jun 30, 2026 | Lippis Daniel J. | CVP, TAVR | open-market sale10b5-1 | 619 | $91.40 | $57K | 40,411 | Jun 30, 2026 |
| Jun 17, 2026 | Zovighian Bernard J | CEO, Director | open-market sale10b5-1indirect | 523 | $87.92 | $46K | 11,517 | Jun 17, 2026 |
| May 29, 2026 | Dahl Andrew M. | SVP, Corporate Controller | open-market sale | 568 | $86.08 | $49K | 15,334 | May 29, 2026 |
| May 27, 2026 | Bobo Donald E JR | CVP,Strategy/Corp Development | open-market saleindirect | 23,145 | $86.42 | $2M | 98,611 | May 27, 2026 |
| May 22, 2026 | Chopra Daveen | CVP, TMTT & Surgical | open-market sale | 1,500 | $84.60 | $127K | 44,324 | May 22, 2026 |
| May 18, 2026 | Lippis Daniel J. | CVP, TAVR | option exercise | 620 | $72.68 | $45K | 41,031 | May 18, 2026 |
| May 18, 2026 | Lippis Daniel J. | CVP, TAVR | open-market sale10b5-1 | 620 | $81.14 | $50K | 40,411 | May 18, 2026 |
| May 15, 2026 | Bobo Donald E JR | CVP,Strategy/Corp Development | open-market sale | 9,968 | $82.07 | $818K | 22,798 | May 18, 2026 |
| May 15, 2026 | Bobo Donald E JR | CVP,Strategy/Corp Development | open-market saleindirect | 8,000 | $81.82 | $655K | 30,970 | May 18, 2026 |
| May 12, 2026 | Zovighian Bernard J | CEO, Director | gift | 26,640 | $0.00 | — | 99,165 | May 12, 2026 |
| May 12, 2026 | Zovighian Bernard J | CEO, Director | giftindirect | 26,640 | $0.00 | — | 48,391 | May 12, 2026 |
| May 12, 2026 | Zovighian Bernard J | CEO, Director | open-market sale10b5-1indirect | 845 | $78.40 | $66K | 47,546 | May 12, 2026 |
| May 12, 2026 | Zovighian Bernard J | CEO, Director | open-market sale10b5-1indirect | 35,506 | $77.92 | $3M | 12,040 | May 12, 2026 |
| May 11, 2026 | Zovighian Bernard J | CEO, Director | option exercise | 47,207 | $0.00 | — | 157,492 | May 12, 2026 |
| May 11, 2026 | Zovighian Bernard J | CEO, Director | tax withholding | 26,198 | $79.96 | $2M | 125,805 | May 12, 2026 |
| May 11, 2026 | Bobo Donald E JR | CVP,Strategy/Corp Development | option exercise | 13,457 | $0.00 | — | 40,235 | May 12, 2026 |
| May 11, 2026 | Bobo Donald E JR | CVP,Strategy/Corp Development | tax withholding | 7,469 | $79.96 | $597K | 32,766 | May 12, 2026 |
| May 11, 2026 | Chopra Daveen | CVP, TMTT & Surgical | option exercise | 13,583 | $0.00 | — | 53,362 | May 12, 2026 |
| May 11, 2026 | Chopra Daveen | CVP, TMTT & Surgical | tax withholding | 7,538 | $79.96 | $603K | 45,824 | May 12, 2026 |
| May 11, 2026 | Ullem Scott B. | CVP, Chief Financial Officer | option exercise | 19,830 | $0.00 | — | 57,744 | May 11, 2026 |
| May 11, 2026 | Ullem Scott B. | CVP, Chief Financial Officer | tax withholding | 11,004 | $79.96 | $880K | 46,740 | May 11, 2026 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Bobo Donald E JR | CVP,Strategy/Corp Development | May 27, 2026 | open-market sale | 22,798 | — | $11M (12) | 6 of 12 |
| Zovighian Bernard J | CEO, Director | Jul 27, 2026 | gift | 98,845 | — | $7M (8) | 5 of 8 |
| Ullem Scott B. | CVP, Chief Financial Officer | May 11, 2026 | option exercise | 57,744 | — | $4M (7) | 7 of 7 |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | Sep 11, 2026 | tax withholding | 43,926 | — | $3M (4) | 0 of 4 |
| Markowitz Wayne | CVP, JAPAC | Sep 14, 2026 | tax withholding | 19,371 | — | $1M (5) | 0 of 5 |
| Lippis Daniel J. | CVP, TAVR | Oct 8, 2026 | option exercise | 40,653 | — | $925K (14) | 14 of 14 |
| Bruls Annette | CVP, EMEACLA | Aug 28, 2026 | open-market sale | 17,984 | — | $238K (1) | 0 of 1 |
| Stone Heisz Leslie | Director | May 8, 2026 | award | 34,199 | — | $218K (1) | 0 of 1 |
| Dahl Andrew M. | SVP, Corporate Controller | Sep 13, 2026 | tax withholding | 14,615 | — | $98K (2) | 0 of 2 |
| Wood Larry L | Global President TAVR & Surg | Aug 18, 2025 | option exercise | 215,850 | — | — | — |
| Loranger Steven R | Director | May 8, 2026 | award | 7,933 | — | — | — |
| Gallahue Kieran | Director | May 8, 2026 | award | 3,251 | — | — | — |
| Mistras Theodora | CVP, Chief Financial Officer | Jul 9, 2026 | award | 87,595 | — | — | — |
| Valeriani Nicholas J | Director | May 8, 2026 | award | 84,423 | — | — | — |
| Sequeira Ramona | Director | May 8, 2026 | award | 6,779 | — | — | — |
| Laviolette Paul A | Director | May 8, 2026 | award | 17,552 | — | — | — |
| Feinberg David T | Director | May 8, 2026 | award | 9,087 | — | — | — |
| Davis Leslie C. | Director | May 8, 2026 | award | 9,834 | — | — | — |
Questions
Are Edwards Lifesciences Corp insiders buying or selling?
Over the twelve months to November 1, 2026, 9 insiders at Edwards Lifesciences Corp sold $28M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $28M. Only open-market purchases and sales are counted.
Who sold the most Edwards Lifesciences Corp stock in the last year?
Bobo Donald E JR (CVP,Strategy/Corp Development) sold $11M in 12 open-market sales over the twelve months to November 1, 2026.
Do Edwards Lifesciences Corp executives sell under 10b5-1 plans?
32 of the 54 open-market sales in the last twelve months (59%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Edwards Lifesciences Corp
- Edwards Lifesciences Corp financial statements
- 1 tracked fund holding EW
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.